Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK   US58933Y1055

MERCK & CO., INC. (MRK)

156
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

12/21/2012 | 05:46am US/Eastern

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.

MAIN FACTS:

-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at tapan.panchal@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
React to this article
Latest news on MERCK & CO., INC.
07/03 Exclusive - Hospira wins French biosimilar drug tender at 45 percent discount
07/01 MERCK : New Findings on Thrombosis Described by Investigators at Merck & Company..
06/30 MERCK : MSD's Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary ..
06/29DJMERCK : Regimen to Reduce Nausea Meets Primary Endpoint
06/29 MERCK : Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine..
06/26 MERCK : to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 2..
06/24 MERCK : Data on Chronic Kidney Disease Reported by Researchers at Merck & Compan..
06/24 MERCK : Ramadan healthcare campaign wins top PR honours
06/21 Chinese firms pour money into U.S. R&D in shift to innovation
06/17DJInspire Pharmaceuticals Settles Federal Fraud Claims
Advertisement
Chart
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
More Financials